Xilio Therapeutics Inc (XLO)
1.14
+0.06
(+5.56%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
Pre-Market: 20:00
Xilio Therapeutics Cash from Financing (Quarterly): 0.954M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.954M |
| December 31, 2023 | -1.634M |
| September 30, 2023 | -2.236M |
| June 30, 2023 | -0.992M |
| March 31, 2023 | -1.688M |
| December 31, 2022 | -0.021M |
| September 30, 2022 | -0.022M |
| Date | Value |
|---|---|
| June 30, 2022 | -0.021M |
| March 31, 2022 | -0.005M |
| December 31, 2021 | 115.83M |
| September 30, 2021 | 0.301M |
| June 30, 2021 | -0.349M |
| March 31, 2021 | 144.89M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.236M
Minimum
Sep 2023
144.89M
Maximum
Mar 2021
19.62M
Average
-0.021M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| Gilead Sciences Inc | -1.361B |
| FibroGen Inc | -0.165M |
| Avalo Therapeutics Inc | 108.61M |
| IGM Biosciences Inc | 0.152M |
| AEON Biopharma Inc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.50M |
| Free Cash Flow | -53.87M |
| Free Cash Flow Per Share (Quarterly) | -0.3762 |
| Free Cash Flow Yield | -171.1% |